Cantheon Capital
VC Fund
Cantheon Capital is a VC fund focused on Biotechnology and Life Science.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 80%
Last updated:
For AI agents: llms.txt
Industries Cantheon Capital invests in
Stages Cantheon Capital invests in
Countries Cantheon Capital invests in
Investment Focus
Industry
- Biotechnology 3 (60%)
- Life Science 2 (40%)
- Pharmaceutical 2 (40%)
- Medical 1 (20%)
- Cannabis 1 (20%)
Stage
- Post-IPO Debt 3 (60%)
- Post-IPO Equity 2 (40%)
Country
- Canada 1 (20%)
- United States 1 (20%)
- United Kingdom 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Oxford Cannabinoid Technologies
|
Oxford Cannabinoid Technologies is a biopharmaceutical company established to combine cannabinoid medicine with world class scientific research and drug development. OCT brings together some of the world’s best medical researchers to develop new therapies for diseases with high unmet medical need. | $713.8K / Post-IPO Debt / Feb 02, 2024 | |
Psycheceutical
|
Psycheceutical is a patented delivery technology that provides safe bioavailable psychedelic pharmaceutical medicines. Their goal is to employ next-generation patented Janus particles and novel delivery technologies to bring safety and efficacy to psychedelic compounds for the medical and pharmaceutical industries. These advanced delivery systemsallow for safe dosage control and consistent desired results. | $1.3M / Post-IPO Debt / Jun 01, 2023 | |
Albert Labs
|
Albert Labs is a fully-integrated biopharmaceutical company bringing innovative prescription medicines to patients with unmet mental health needs. Its team of experts leverage advanced culture technology and natural extraction, coupled with a comprehensive regulatory approach, to accelerate the development of mental health drugs, for which patientneeds are both urgent and unmet. Albert Labs looks to develop solutions through an approved, fast-track clinical pathway focusing on Real World Evidence (RWE). RWE studies are a recognised clinical pathway, heavily used in oncology and recently, in the successful development of COVID-19 vaccines. | $605K / Post-IPO Debt / Mar 23, 2023 | |
Psyence
|
Psyence is a life science biotechnology company that has pioneered the use of natural psilocybin to heal psychological trauma and the diagnosable disorders that can result from it, including anxiety, depression, PTSD, stress, grief, and bereavement. It focuses on these diseases in the context of palliative care.The company conducts scientificresearch and development of psilocybin medical products for research institutions, clinics, and psilocybin-containing products that are regulatory-compliant. It is also working on functional mushroom nutraceutical products to treat depression, anxiety, and sleep disorders. | $1.4M / Post-IPO Equity / Mar 23, 2023 | |
Zelira Therapeutics
|
Zelira Therapeutics Ltd is a leading global therapeutic medicinal cannabis company with access to the world’s largest and fastest growing cannabis markets. | $8.6M / Post-IPO Equity / Feb 15, 2023 |
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Cantheon Capital invest in?
Cantheon Capital invests primarily in Biotechnology, Life Science and Pharmaceutical startups, most often at Post-IPO Debt and Post-IPO Equity stage. Most of the 5 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Cantheon Capital last invest?
The most recent investment recorded for Cantheon Capital closed in Feb 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
